Triple Negative Breast Cancer with Andrew Seidman, MD and Joyce O'Shaughnessy, MD: Case 2 - Episode 3
What are the main characteristics of this patient that make her an appropriate candidate for eribulin therapy?
Metastatic breast cancer patients such as this patient, when we’re thinking about treatment options, we’d like to offer eribulin to patients that came as close to the clinical trial setting that led to the definitive data. In this case that is improvement of overall survival, and that clinical trial was the EMBRACE trial. Those patients had been treated with an anthracycline and a taxane, and had received at least two prior regimens for metastatic breast cancer.
Triple Negative Breast Cancer: Case 2
Connie C is a 56-year-old television producer for a local news station, her medical history is unremarkable for any chronic conditions.
In September of 2014, after presenting to her PCP with a palpable breast mass and fatigue of several months’ duration she underwent a left mammogram revealing a large breast mass.
In February of 2015, she returns with increasing fatigue and back pain; her CT scan shows progression of the hepatic lesions, and bone scan shows new lesions in the T4 and T5 vertebra. At the time of progression, her ECOG performance status (PS) is 1.
In June of 2015, she returns for follow up with worsening back pain and intermittent dyspnea. Her CT scan at the time of progression shows the bone lesions worsening and several new bilateral pulmonary lesions.